# Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer

> **NCT01147991** · PHASE1 · COMPLETED · sponsor: **Cancer Research UK** · enrollment: 16 (actual)

## Conditions studied

- Gastric Cancer
- Head and Neck Cancer
- Lymphoma
- Lymphoproliferative Disorder
- Nonneoplastic Condition

## Interventions

- **BIOLOGICAL:** EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01147991
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2012-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01147991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01147991, "Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01147991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*